Atriance (nelarabine)

pCPA File Number: 22515
Negotiation Status:
Negotiations were not pursued
Indication(s):
Nelarabine (Atriance) for addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL).
Sponsor/Manufacturer:
Sandoz Canada Inc.
CADTH Project Number:
PC0307-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: